# Karyopharm (KPTI) — Earnings

KPTI · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/kpti/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$2.32 |
| EPS estimate | −$1.37 |
| EPS surprise | −69.13% |
| Revenue surprise | +3.85% |
| Revenue | $33.4M |
| Revenue estimate | $32.2M |
| Reported | Aug 13, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1503802/000119312526347906/kpti-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/66efee46-d3ab-a45b-0d1a-a4d1f8aaebf6.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 13, 2026 | −$1.37 | −$2.32 | -69.13% | $32.2M | $33.4M |
| Q1 2026 | May 14, 2026 | −$1.42 | −$1.24 | 12.50% | $31.4M | $35.1M |
| Q4 2025 | Feb 12, 2026 | −$1.99 | −$5.71 | -186.32% | $35.1M | $34.1M |
| Q3 2025 | Nov 3, 2025 | −$3.47 | −$3.82 | -10.23% | $42.1M | $44.0M |
| Q2 2025 | Aug 11, 2025 | −$4.08 | −$4.32 | -5.84% | $38.0M | $37.9M |
| Q1 2025 | May 12, 2025 | −$4.42 | −$2.77 | 37.32% | $35.1M | $30.0M |
| Q4 2024 | Feb 19, 2025 | −$3.92 | −$3.60 | 8.20% | $35.7M | $30.5M |
| Q3 2024 | Nov 5, 2024 | −$3.94 | −$3.90 | 1.09% | $37.9M | $38.8M |
| Q2 2024 | Aug 6, 2024 | −$4.47 | −$3.00 | 32.85% | $36.2M | $42.8M |
| Q1 2024 | May 8, 2024 | −$5.01 | −$4.80 | 4.15% | $34.5M | $33.1M |
| Q4 2023 | Feb 29, 2024 | −$4.65 | −$5.40 | -16.13% | $35.4M | $33.7M |
| Q3 2023 | Nov 2, 2023 | −$4.20 | −$4.50 | -7.14% | $37.3M | $36.0M |
| Q2 2023 | Aug 2, 2023 | −$5.13 | −$4.35 | 15.26% | $35.7M | $37.6M |
| Q1 2023 | May 4, 2023 | −$5.51 | −$4.50 | 18.36% | $36.3M | $38.7M |
| Q4 2022 | Feb 15, 2023 | −$5.30 | −$6.45 | -21.81% | $34.4M | $33.6M |
| Q3 2022 | Nov 3, 2022 | −$8.48 | −$6.75 | 20.43% | $34.8M | $36.1M |
| Q2 2022 | Aug 4, 2022 | −$9.50 | −$9.30 | 2.11% | $36.0M | $39.7M |
| Q1 2022 | May 5, 2022 | −$9.47 | −$7.95 | 16.01% | $34.4M | $47.7M |
| Q4 2021 | Feb 8, 2022 | −$6.79 | $6.90 | 201.66% | $52.7M | $126.3M |
| Q3 2021 | Nov 3, 2021 | −$10.10 | −$10.35 | -2.48% | $26.2M | $37.7M |

## Frequently Asked Questions

### When did Karyopharm (KPTI) last report earnings?

Karyopharm last reported on Aug 13, 2026, covering fiscal Q2 2026.

### Did KPTI beat earnings estimates?

No. Karyopharm reported EPS of −$2.32 for Q2 2026 against a −$1.37 estimate — a 69.13% miss.

### How much revenue did KPTI report last quarter?

Karyopharm reported $33.4M in revenue for Q2 2026, against a consensus estimate of $32.2M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).